Marilyn Ader, PhD
Associate Director, Diabetes & Obesity Research Institute
|Associate Professor, Biomedical Sciences|
Awards and Activities
|Standing Member, NIH Study Section (IPOD)||2008|
|Co-Editor-in-Chief, Obesity||2011 - 2012|
|Editorial Board Member, American Journal of Physiology||1998 - 2006|
|American Diabetes Association||1984|
|The Endocrine Society||1986|
|European Association for the Study of Diabetes||1986|
|International Diabetes Federation||1986|
|American Physiological Society||1988|
|The Obesity Society ||1995|
|Public Responsibility in Medicine and Research (PRIM&R)||2013|
The overall focus of Dr. Ader¿s laboratory is the pathogenesis of Type 2 diabetes, with an integrative perspective on the impact of obesity on insulin sensitivity, insulin secretion, and hepatic insulin clearance. Her research examines the mechanisms by which multiple organ systems interact to maintain glucose homeostasis in the face of environmental and pharmacologic insults. One of her primary research projects investigates the mechanisms by which FDA-approved psychotropic medications induce obesity and glucose dysregulation. These studies have had major translational and public health impact, and involve both large animal studies and collaborative work of psychiatric patients. Additional research in Dr. Ader¿s lab examines the role of liver insulin clearance in determining insulin sensitivity and fasting insulin levels, and studies the impact of obesity on the contribution of liver clearance versus pancreatic ß-cell insulin secretion to fasting hyperinsulinemia. Dr. Ader is also pursuing novel pancreatic islet transplant research for possible clinical treatment of Type 1 diabetes.
Contributions of Dr. Ader¿s research include uncovering critical mechanisms by which atypical antipsychotics can disrupt carbohydrate metabolism and body composition. Her group demonstrated that a major action of insulin ¿ to suppress glucose production by liver ¿ may actually occur via indirect action of the hormone on extrahepatic tissues. Her work has also contributed to exposing limitations in the widespread use of surrogate fasting-based measures to detect insulin resistance in clinical studies.
Current investigations include:
Examining antipsychotic drug effects on obesity and insulin secretory function. Testing ability of surrogate measures (e.g. HOMA-IR) to detect insulin resistance. Quantifying in vivo functionality of novel pancreatic islet transplants for future diabetes treatment.
- Ader M, Stefanovski D, Kim SP, Richey JM, Ionut V, Catalano KJ, Hucking K, Ellmerer M, Van Citters G, Hsu IR, Chiu JD, Woolcott OO, Harrison LN, Zheng D, Lottati M, Kolka CM, Mooradian V, Dittmann J, Yae S, Liu H, Castro AV, Kabir M, Bergman RN: Variable hepatic insulin clearance with attendant insulinemia is the primary determinant of insulin sensitivity in the normal dog. Obesity (Silver Spring), , 2013
- Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, Kabir M, Bergman RN: Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes, 54(3): 862-71, 2005
- Ader M, Garvey WT, Phillips LS, Nemeroff CB, Gharabawi G, Mahmoud R, Greenspan A, Berry SA, Musselman DL, Morein J, Zhu Y, Mao L, Bergman RN: Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. Journal of psychiatric research, 42(13): 1076-85, 2008
- Bergman RN, Ader M, Huecking K, Van Citters G: Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes, 51 Suppl 1: S212-20, 2002
- Ader M, Bergman RN: Peripheral effects of insulin dominate suppression of fasting hepatic glucose production. Am. J. Physiol., 258(6 Pt 1): E1020-32, 1990
- Bergman RN, Finegood DT, Ader M: Assessment of insulin sensitivity in vivo. Endocr. Rev., 6(1): 45-86